COMMUNIQUÉS West-GlobeNewswire

SafeSpace Global Corporation (OTCID: SSGC) Appoints Harvest Communications as Investor Relations and Corporate Communications Consulting Agency
17/12/2025
Knoxville, TN, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), an AI technology company dedicated to protecting lives across education, healthcare, transportation, and correctional [...]
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
17/12/2025
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain PHOENIX, Dec. 17, 2025 (GLOBE [...]
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
17/12/2025
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 [...]
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
17/12/2025
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune [...]
Acentra Health Appoints President and Chief Operations Officer Meghan Harris to Its Board of Directors
17/12/2025
Long-time healthcare operations leader brings strategic insight, client-first vision, and operational excellence to board role MCLEAN, Va., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health [...]
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
17/12/2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy
17/12/2025
First-of-its-kind semi-synthetic vitamin E product enables scalable, FDA-compliant production of Peptinovo’s proprietary cancer prodrugs ANN ARBOR, Mich., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann [...]
Kohope Medical Devices Announces 40% Production Capacity Increase and New Distribution Center to Serve North American Market
17/12/2025
Shanghai Kohope Medical Devices Co., Ltd. invests $2.5 million in facility expansion hub to meet surging demand for syringes and medical needles across United States and Canada. SHANGHAI, Dec. 17, 2025 (GLOBE NEWSWIRE [...]
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
17/12/2025
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid ® -ineligible patients, representing a significant population with few effective [...]
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
17/12/2025
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable [...]
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
17/12/2025
NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update [...]
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
17/12/2025
Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up [...]
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
17/12/2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive [...]
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
17/12/2025
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications Collaboration supports [...]
Secura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome
17/12/2025
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that [...]
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases
17/12/2025
All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needs Addition is advancing a robust pipeline of PRINTed therapeutics for chronic and [...]
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a [...]

Pages